Antibodies

14 Jun 2018 New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway
14 Jun 2018 argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
14 Jun 2018 Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
13 Jun 2018 Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
13 Jun 2018 CStone Pharmaceuticals Initiates Two Pivotal Phase II Studies of the Anti-PD-L1 Monoclonal Antibody CS1001
13 Jun 2018 FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
13 Jun 2018 Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
13 Jun 2018 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
12 Jun 2018 Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
12 Jun 2018 ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease
11 Jun 2018 GT Biopharma Announces Preliminary Clinical Results From Interim Review of Phase 1/2 Clinical Trial of OXS-1550, its Bi-Specific Antibody Drug Conjugate
08 Jun 2018 European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
08 Jun 2018 FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
05 Jun 2018 New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive results for the treatment of active Crohn’s disease in data presented at Digestive Disease Week 2018
05 Jun 2018 FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors
05 Jun 2018 Mabion S.A. completes marketing authorisation application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)
04 Jun 2018 Alexo Therapeutics Presents Preliminary Results from ALX-148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
04 Jun 2018 Agenus Presents Clinical Responses of AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) at ASCO 2018
04 Jun 2018 Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018
04 Jun 2018 Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
04 Jun 2018 CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting
04 Jun 2018 Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018
04 Jun 2018 New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma
04 Jun 2018 Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma
04 Jun 2018 Merck’s KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top